AI assistant
Adocia — Share Issue/Capital Change 2016
Mar 25, 2016
1074_iss_2016-03-25_9f906e4f-71d7-4ee6-b46a-3eb8c40e6919.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
PRESS RELEASE
ADOCIA confirms its eligibility for the PEA – PME
Lyon, France, March 25, 2016 - ADOCIA (Euronext Paris: FR0011184241 – ADOC) confirms its eligibility for the "PEA – PME" stock savings tax regime, which decree has been published in the French Journal Officiel on March 4, 2014 (Decree n ° 2014-283), and which entered into force on March 6, 2014.
To be eligible for the "PEA – PME", the shares must have been issued by a company whose market capitalization is below one billion euros, of which no legal person holds more than 25% of its capital, which has less than 5,000 employees, and an annual turnover not exceeding 1 500 million euros or a total balance sheet less than 2 000 million euros.
Adocia meets all of these conditions.
About ADOCIA
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of alreadyapproved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapidacting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).
In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.
Adocia's extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.
Adocia aims to deliver "Innovative medicine for everyone, everywhere."
To learn more about Adocia, please visit us at www.adocia.com
For more information please contact:
| Adocia | Adocia Press Relations France | Adocia Press Relations Europe |
|---|---|---|
| Gérard Soula | ALIZE RP | MC Services AG |
| Chairman and CEO | Caroline Carmagnol et Florence | Raimund Gabriel |
| [email protected] | Portejoie | [email protected] |
| Tél. : +33 4 72 610 610 | [email protected] | [email protected] |
| [email protected] | Tél. : +49 89 210 228 0 | |
| Tél. : + 33 1 44 54 36 61 |